|Bid||167.58 x 800|
|Ask||176.72 x 900|
|Day's Range||167.24 - 176.00|
|52 Week Range||90.14 - 182.23|
|Beta (3Y Monthly)||3.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||188.17|
HENDERSON, NV / ACCESSWIRE / March 21, 2019 / The electricity consumption of cannabis grow houses is staggering when compared to business and residential use. In 2015, the average electricity consumption ...
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $170.27, moving +1.28% from the previous trading session.
CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry. As we look to the future, these smaller companies may play a role in securing potential opportunities for the cannabis industry. ParcelPal Technology Inc (PTNYF) (PKG), Curaleaf Holdings Inc (CURLF) (CURA.CN), Zynerba Pharmaceuticals Inc (ZYNE), and GW Pharmaceuticals plc (GWPH) represent 4 marijuana stocks getting a boost from today's headlines.
in early November, writing this: "Investors need to risk a close below $130 to trade GWPH from the long side. Looking back at the price action since the beginning of November, chart below, we can see traders may have gone long above $150 and then were quickly stopped out with a loss about two weeks later. GWPH is trading above the slightly rising 200-day moving average line and the bullish 50-day average line.
GW Pharmaceuticals Plc said Monday it is selling its Rare Pediatric Disease Priority Review Voucher for $105 million. The company, which was the first to receive U.S. Food and Drug Administration approval for a cannabis-based drug, received the PRV when it was developing that treatment called Epidiolex, which treats seizures associated with two types of rare childhood epilepsy. The PRV program aims to encourage companies to invest in R&D for rare pediatric diseases. The buyer is entitled to a priority, expedited review, with the aim of helping to bring drugs to market that treat rare diseases. "The sale of the PRV provides an important source of non-dilutive capital to help advance our pipeline and to continue to invest in the EPIDIOLEX commercial launch in both the U.S. and Europe," GW Pharma Chief Executive Justin Gover said in a statement. Shares were not yet active premarket, but have gained 42.5% in the last 12 months, while the S&P 500 has gained 2.6%.
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105,000,000. GW was awarded the voucher under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. GW Research Ltd. received the PRV when EPIDIOLEX® (cannabidiol) was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies.
GW Pharmaceuticals plc (GWPH) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, pharmaceuticals, tobacco, and the $3.2 trillion wellness industry, as the cultural renaissance just gets underway. It's just starting to disrupt countless, multi-billion-dollar industries, especially the $4.2 trillion wellness industry. The Yield Growth Corporation (BOSS)(BOSQF), for example, has engaged the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) to identify and quantify anti-inflammatory and other bioactive compounds in its hemp root oil derived by Yield Growth's proprietary extraction methods.
HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are ...
Q4 2018 GW Pharmaceuticals PLC Earnings Call (Transition to 2019 Fiscal Period)
HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits ...
Cannabis stocks have been red-hot so far in 2019, and Piper Jaffray analyst Michael Lavery said Monday that the outlook for medical cannabis is brighter than ever. The medical expert Lavery met with said vapor is the safest and most effective way to deliver cannabis treatment, while tinctures are also effective, with a longer onset period.
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
Institutional demand, liquidity, perception and price can turn the cannabis industry into a once in a lifetime investing opportunity.
GW, Hasbro, Salesforce, American Express and Intuit highlighted as Zacks Bull and Bear of the Day
GW Pharmaceuticals plc's (NASDAQ:GWPH): GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The US$5.4b market-capRead More...